Search results
Showing 1 to 15 of 160 results for asthma
In development [GID-NG10186] Expected publication date: 27 November 2024
This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS25Show all sections
Sections for QS25
- Quality statements
- Quality statement 1 (developmental): Objective tests to support diagnosis
- Quality statement 2: Written personalised action plan
- Quality statement 3: Monitoring asthma control
- Quality statement 4: Follow-up by general practice after emergency care
- Quality statement 5 (developmental): Suspected severe asthma
- Update information
- About this quality standard
Asthma: diagnosis, monitoring and chronic asthma management (NG80)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
All NICE products on asthma. Includes any guidance, advice and quality standards.
This indicator covers the contractor establishing and maintaining a register of patients with asthma aged 5 or over. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM165
This indicator covers the percentage of patients with asthma on the register, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control using a validated asthma control questionnaire (including assessment of short acting beta agonist use), a recording of the number of exacerbations and a written personalised action plan. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM167
This indicator covers the percentage of patients with asthma on the register from (start date) with a record of spirometry and 1 other objective test (FeNO or reversibility or variability) between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM166
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
This indicator covers the percentage of patients with asthma on the register aged 19 or under, in whom there is a record of smoking status (active or passive) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM168
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Asthma. Patient decision aid on asthma inhalers and climate change
Asthma inhalers and climate change What is this decision aid about? Inhalers are a key part of treating your asthma. The...